Determining the Safety of L-serine in ALS

NCT ID: NCT01835782

Last Updated: 2015-07-30

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-01-31

Brief Summary

The purpose of this study is to determine the safety of L-Serine in subjects with Amyotrophic Lateral Sclerosis (ALS) at varied doses.

Detailed Description

Previous studies into the Guamian ALS-Parkinson's Dementia complex has identified β-methylamino-L-alanine (BMAA), as a potential neurotoxin responsible for this disease. BMAA is a non-essential amino acid and is produced by a cyanobacterium which is present in all ecosystems. Subsequently several groups have identified high concentrations of BMAA in brain tissues of patients from North America and Europe with several neurodegenerative diseases including ALS, Parkinson's Disease and Alzheimer's Diseases. It has been hypothesized that chronic intake of BMAA in the diet leads to mis-incorporation of the amino acid into brain proteins, where it produces slow neuronal damage and recent evidence has shown that BMAA is mis-incorporated into proteins in neuronal cell lines via seryl tRNA synthetase, thereby producing protein mis-folding and protein aggregates, leading to cell death. It has been demonstrated in mammalian neuronal cell cultures that exogenous L-serine could prevent the BMAA neurotoxin from being mis-incorporated into proteins, thereby preventing cell death and that very high doses of L-serine may compete with the transport of a number of non-essential amino acids across the blood-brain barrier via the y+ transporter. These findings have led us to believe that high doses of L-serine could possibly stop the mis-incorporation of BMAA into brain proteins which in turn would slow or even abate the progression of ALS. This study will determine the safety of different doses of L-serine given to ALS subjects at 0.5 gm twice daily (BID), 2.5gm BID, 7.5g BID or 15 grams BID for six months.

Conditions

Amyotrophic Lateral Sclerosis (ALS)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: FACTORIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

2.5 grams BID

5 Patients will be evenly randomized into this group

Group Type: ACTIVE_COMPARATOR

L-Serine

Intervention Type: DRUG

.5 grams BID

5 Patients will be evenly randomized into this group

Group Type: ACTIVE_COMPARATOR

L-Serine

Intervention Type: DRUG

7.5 grams BID

5 Patients will be evenly randomized into this group

Group Type: ACTIVE_COMPARATOR

L-Serine

Intervention Type: DRUG

15 grams BID

5 Patients will be evenly randomized into this group

Group Type: ACTIVE_COMPARATOR

L-Serine

Intervention Type: DRUG

Interventions

L-Serine

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Age 18-85

2. Male or Female

3. Clinically diagnosed with probable or definite ALS based on El Escorial criteria

4. ALSFRS-R > 25

5. Able to provide informed consent to and comply with all medical procedures

Exclusion Criteria

1. Outside age range of 18-85

2. Subjects with forced vital capacity (FVC) below 60%

3. Evidence of any motor neuron disease for over 3 years

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Institute for Ethnomedicine

UNKNOWN

Sponsor Role: collaborator

Phoenix Neurological Associates, LTD

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Todd D Levine, MD

Role: PRINCIPAL_INVESTIGATOR

Phoenix Neurological Associates, LTD

Locations

Phoenix Neurological Associates

Phoenix, Arizona, United States

Forbes Norris MDA/ALS Research Center

San Francisco, California, United States

Countries

United States

Other Identifiers

IND

Identifier Type: OTHER

Identifier Source: secondary_id

L-Serine2013

Identifier Type: -

Identifier Source: org_study_id